SR One Capital Management Discloses Stake in Kala Bio
Ticker: KALA · Form: SC 13D · Filed: Jul 8, 2024 · CIK: 1479419
Sentiment: neutral
Topics: ownership-change, filing, pharmaceuticals
Related Tickers: KALA
TL;DR
**SR ONE CAPITAL MANAGEMENT NOW HAS A SIGNIFICANT STAKE IN KALA BIO (KALA).**
AI Summary
SR One Capital Management, LLC, along with affiliated entities Simeon George and SR One Capital Fund II Aggregator, LP, has filed a Schedule 13D on July 8, 2024, indicating a change in beneficial ownership of Kala Bio, Inc. The filing does not specify the exact number of shares or percentage of ownership, but it signifies a significant stake held by these entities in the pharmaceutical company.
Why It Matters
This filing signals a significant investment or change in control interest by a major venture capital firm in Kala Bio, potentially influencing the company's strategic direction and future operations.
Risk Assessment
Risk Level: medium — The filing indicates a change in beneficial ownership by a significant investor, which could lead to strategic shifts or potential activism, but does not detail specific actions or a controlling stake.
Key Players & Entities
- SR One Capital Management, LLC (company) — Filing entity
- KALA BIO, Inc. (company) — Subject company
- Simeon George (person) — Group member associated with filing entity
- SR One Capital Fund II Aggregator, LP (company) — Group member associated with filing entity
- SR One Capital Partners II, LP (company) — Group member associated with filing entity
- Sasha Keough (person) — Contact person for filing entity
FAQ
What is the exact percentage of Kala Bio, Inc. shares beneficially owned by SR One Capital Management and its affiliates?
The provided filing excerpt does not specify the exact percentage or number of shares beneficially owned by SR One Capital Management, LLC and its group members.
When was the Schedule 13D filing submitted to the SEC?
The Schedule 13D filing was submitted to the SEC on July 8, 2024.
What is the primary business of Kala Bio, Inc.?
Kala Bio, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.
Who is listed as the contact person for the filing entity?
Sasha Keough, c/o SR One Capital Management, LP, is listed as the contact person.
What was the former name of Kala Bio, Inc.?
The former name of Kala Bio, Inc. was Kala Pharmaceuticals, Inc., with a name change date of December 23, 2009.
Filing Stats: 2,625 words · 11 min read · ~9 pages · Grade level 12.4 · Accepted 2024-07-08 20:54:55
Key Financial Figures
- $0.001 — Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securiti
- $5.85 — of Common Stock at a purchase price of $5.85 per share and (ii) 4,110 shares of Seri
- $585.00 — ies H Preferred) at a purchase price of $585.00 per share. Each share of Series H Prefe
Filing Documents
- d861628dsc13d.htm (SC 13D) — 99KB
- d861628dex991.htm (EX-99.1) — 8KB
- d861628dex992.htm (EX-99.2) — 108KB
- 0001193125-24-176447.txt ( ) — 217KB
From the Filing
SC 13D 1 d861628dsc13d.htm SC 13D SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* KALA BIO, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 483119202 (CUSIP Number) Sasha Keough c/o SR One Capital Management, LP 985 Old Eagle School Road, Suite 511 Wayne, PA 19087 (410) 800-7503 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 28, 2024 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 483119202 13D Page 2 of 25 Pages 1 NAMES OF REPORTING PERSONS SR One Capital Fund II Aggregator, LP 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)(b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) WC 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 0 shares 8 SHARED VOTING POWER 445,643 shares 9 SOLE DISPOSITIVE POWER 0 shares 10 SHARED DISPOSITIVE POWER 445,643 shares 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 445,643 shares 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.99%(1) 14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN (1) Based on 4,458,909 shares of common stock, par value $0.001 per share (Common Stock), of KALA BIO, Inc. (the Issuer) reported outstanding as of June 26, 2024 on the Issuers Form 8-K filed with the Securities and Exchange Commission (the SEC) on June 27, 2024. CUSIP No. 483119202 13D Page 3 of 25 Pages 1 NAMES OF REPORTING PERSONS SR One Capital Partners II, LP 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)(b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) AF 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 0 shares 8 SHARED VOTING POWER 445,643 shares 9 SOLE DISPOSITIVE POWER 0 shares 10 SHARED DISPOSITIVE POWER 445,643 shares 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 445,643 shares 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.99%(1) 14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN (1) Based on 4,458,909 shares of Common Stock of the Issuer reported outstanding as of June 26, 2024 on the Issuers Form 8-K filed with the SEC on June 27, 2024. CUSIP No. 483119202 13D Page 4 of 25 Pages 1 NAMES OF REPORTING PERSONS SR One Capital Management, LLC 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)(b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) AF 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 0 shares 8 SHARED VOTING POWER 445,643 shares 9 SOLE DISPOSITIVE POWER 0 shares 10 SHARED DISPOSITIVE POWER 445,643 shares 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 445,643 shares 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.99%(1) 14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO (1) Based on 4,458,909 shares of Common Stock of the Issuer reported outstanding as of June 26, 202